Transcription of OCREVUS Prescribing Information - Genentech
{{id}} {{{paragraph}}}
Example: bachelor of science
OCREVUS Prescribing Information - Genentech
HIGHLIGHTS OF Prescribing INFORMATIONT hese highlights do not include all the Information needed to use OCREVUS safely and effectively. See full Prescribing Information for (ocrelizumab) injection, for intravenous useInitial Approval: 2017---------------------------RECENT MAJOR CHANGES---------------------------Dosage and Administration ( , ) 12/2020 Warnings and Precautions( , )11/2020---------------------------INDIC ATIONS AND USAGE---------------------------- OCREVUS is aCD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS),to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults(1) Primary progressive MS, in adults(1)-----------------------DOSAGE AND ADMINISTRATION----------------------- hepatitis B virusand quantitative serum immunoglobulin screening are required before the first dose ( ) Pre-medicat
Hepatitis B Virus Screening Prior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening. OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBVtests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: